AUS
NZ
UK
CA
USA
IND
Healt
ACCC Approval of Sigma-Chemist Warehouse Merger Sparks Market Interest
November 07, 2024 03:57 PM AEDT| By Team Kalkine MediaHighlights,ACCC grants approval for Sigma Healthcare and Chemist Warehouse merger.,Court-enforceable undertaking ensures fair market competition.,Chemist Warehouse to enter ASX without an IPO fanfare.,The Australian Competition and Consumer Commissio...
Amplia Therapeutics Successfully Raises $13 Million via Share Allotment
November 07, 2024 03:41 PM AEDT| By Team Kalkine MediaHighlights:,Amplia Therapeutics Ltd. successfully raised $13 million through an institutional placement.,Over 67 million shares were allotted at a price of $0.115 each, strengthening the company’s financial position.,The company is advancing its rese...
Sigma (ASX:SIG) Shares Rise 30% After Chemist Warehouse Merger Gets ACCC Green Light
November 07, 2024 03:02 PM AEDT| By Team Kalkine MediaHighlights:,Sigma Healthcare's share price surged 31% following the approval of its merger with Chemist Warehouse.,The Australian Competition & Consumer Commission (ACCC) cleared the merger with specific conditions, including a court-enforceable unde...
Sigma Healthcare Moves Forward with Merger as ACCC Approves Deal with Chemist Warehouse
November 07, 2024 02:26 PM AEDT| By Team Kalkine MediaHighlights,The Australian Competition and Consumer Commission (ACCC) approves Sigma Healthcare’s merger with Chemist Warehouse Group (CWG), with conditions.,Sigma to acquire CWG for shares and $700m in cash, resulting in Chemist Warehouse shareholder...
Neuren’s FY2024: Revenue Surge from Tax Credits & Drug Partnerships
November 07, 2024 11:23 AM AEDT| By Team Kalkine MediaHighlights,Neuren,forecasts FY2024 income in the range of $216 million to $218 million.,Expected $17 million tax credit due to recognized New Zealand tax losses.,Acadia Pharmaceuticals projects $340-$350 million in sales for their partnered neurologi...
Sigma Healthcare Secures ACCC Approval for Chemist Warehouse Merger
November 07, 2024 11:04 AM AEDT| By Team Kalkine MediaHighlights,ACCC grants approval for Sigma Healthcare’s merger with Chemist Warehouse.,Sigma commits to competitive practices and pharmacy service obligations.,Reverse acquisition places Chemist Warehouse shareholders with a major stake.,Sigma Healthc...
Key ASX Penny Stocks for November 2024 Identified
November 06, 2024 06:56 PM AEDT| By Team Kalkine MediaHighlights:,The ASX200 is showing signs of upward momentum, influenced by positive movements on Wall Street and global events such as China’s National People’s Congress.,Penny stocks on the ASX continue to offer high-growth opportunities, particularl...
Alterity’s 'Iron Overload in Brain' Thesis Endorsed by Prominent Publication
November 06, 2024 06:21 PM AEDT| By Team Kalkine MediaHighlights:,Alterity Therapeutics (ASX) receives peer-reviewed recognition for its neurological drug candidate ATH434 in,Metallomics,.,Respiri (ASX) poised to benefit from new US reimbursement rules for remote patient monitoring, boosting market pote...
Neuren Pharmaceuticals Shares Surge 6% on $150 Million PRV Sale
November 06, 2024 03:52 PM AEDT| By Team Kalkine MediaHighlights,Neuren Pharmaceuticals' stock rises 6%, marking its biggest intraday gain since September 27.,The company will receive one-third of the $150 million from the sale of a U.S. FDA pediatric disease priority review voucher (PRV).,Despite the s...
Insider Confidence Rises as Mesoblast Executives Acquire Additional Shares
November 06, 2024 03:28 PM AEDT| By Team Kalkine MediaHighlights,Mesoblast insiders increase holdings, signaling confidence.,Gregory George makes largest purchase, valued at AU$15 million.,Insider ownership of Mesoblast totals around AU$355 million, approximately 24% of the company.,Mesoblast Limited (A...
Tryptamine Therapeutics Advances Clinical Strategy with Board Reshuffle and Strategic Placement
November 06, 2024 02:29 PM AEDT| By Team Kalkine MediaHighlights,Tryptamine Therapeutics acknowledges Peter Molloy's contributions amid board transition.,Strategic placement to support TRP-8803 trial advancements.,New focus on clinical,expertise,with the appointment of Dr. Daniel Tillett.,Tryptamine The...
CardieX Limited (ASX:CDX): Exploring the Journey to Financial Success
November 06, 2024 02:16 PM AEDT| By Team Kalkine MediaHighlights,CardieX Limited is anticipated to achieve profitability by 2026.,Forecasts suggest a strong annual growth rate of 91%.,The company holds a debt level of 79% of its equity.,CardieX Limited (ASX:CDX) is positioned to reach a significant mile...
Freedom Care Group Faces Potential NDIS Ban Amid Program Audit
November 06, 2024 01:29 PM AEDT| By Team Kalkine MediaHighlights,Freedom Care Group faces potential license revocation by NDIS.,Cash flow impact as NDIS program contributes significantly to revenue.,Review triggered following a payment suspension and ongoing audit.,Freedom Care Group (ASX:FCG) recently...
Neuren Pharmaceuticals Gains $50 Million from Priority Review Voucher Sale
November 06, 2024 11:18 AM AEDT| By Team Kalkine MediaHighlights,Neuren,Pharmaceuticals secures $50 million from FDA voucher sale.,The sale is linked to Acadia Pharmaceuticals' Rett syndrome treatment, DAYBUE.,Funds are expected to support,Neuren’s,ongoing neurodevelopmental research.,Neuren Pharmaceuti...
CSL Shares Lag Despite Market Highs, Analysts Remain Optimistic
November 05, 2024 04:57 PM AEDT| By Team Kalkine MediaHighlights,Stock Dip:,CSL shares down nearly 1% in 2024, trading at AU$285.30, off July highs of over AU$312.,Challenges Identified:,Weighed down by the underperformance of Vifor Pharma and regulatory setbacks.,Analyst Optimism:,Brokers maintain a "b...
Biotech Boards That May Face a ‘Second Strike’ Highlighted
November 05, 2024 03:41 PM AEDT| By Team Kalkine MediaHighlights:,A number of biotech companies are facing 'second strike' motions during this AGM season, potentially leading to board spills.,Botanix Pharmaceuticals is advancing its US rollout of Sofdra, despite some shareholder opposition to director p...
Recce Pharmaceuticals Reaches Dosing Milestone in Skin Infection Trial
November 05, 2024 02:58 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals reaches milestone in Phase II trial for R327G gel.,Positive responses,observed,, with no reported Serious Adverse Events.,Trial results,demonstrate,potential in addressing complex skin infections.,Recce Pharmaceutical...
Recce Pharmaceuticals Shows Positive Results in Phase 2 Trial of Topical Gel R327G
November 05, 2024 12:50 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals’ R327G Phase 2 trial meets primary endpoints with promising patient outcomes.,Interim results reveal strong therapeutic responses in patients treated for bacterial skin infections.,The trial reaffirms R327G’s safety a...
PYC Therapeutics Advances Retinitis Pigmentosa 11 Study to Final Stages
November 05, 2024 12:07 PM AEDT| By Team Kalkine MediaHighlights,PYC Therapeutics advances its treatment study for Retinitis Pigmentosa 11.,Higher doses of VP-001 approved for testing in second patient group.,Company aims to,seek,fast-track status from U.S. FDA for this research.,PYC Therapeutics (ASX:P...
Imugene’s (ASX:IMU) VAXINIA Trial Shows Promising Progress in Bile Tract Cancer Treatment
November 05, 2024 11:24 AM AEDT| By Team Kalkine MediaHighlights,Imugene,achieves significant milestone in bile tract cancer treatment.,Patient in VAXINIA Phase 1 trial,maintains,complete response after two years.,U.S. patent extended to 2040, boosting longevity of CF33 oncolytic virotherapy.,Imugene Lt...
Advertise your brand on Kalkine Media